Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12240862-B2

Patent

Publication Date

2025-03-04

Expiration Date


Abstract

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Core Innovation

The invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, defined by X5 being N and X7 being CH or CF, together with variable substituents R1 through R17 and additional parameters including L, q, and n. The structure includes extensive substituent definitions for R1, R2, R3, R4, R6, R8, R9, R12, R13, R14, R15, and R17, as well as substituent sets Z1, Z1a, Z1b, R20, R21, and R22 in some embodiments.

A central structural aspect is that R2 and R3 are taken together with the atoms to which they are attached to form an optionally substituted 6 to 8 membered heterocyclyl ring. The Formula I framework further defines R6 through multiple functional-group and linker options, including -L-R13, where L is C1-8 alkylene, C1-8 haloalkylene, or 5-10 membered heteroarylene, and R13 is selected from enumerated functional-group and ring-containing options.

The disclosed chemical space is supported by numerous example structures and partial formula schematics featuring imidazo[1,2-a]pyridine and pyrrolo[2,3-b]pyridine scaffolds linked to sulfonamide, carboxamide, or related heteroaromatic side chains. The examples vary substituents such as cyclopropylmethyl, difluoromethyl or trideuteriomethyl groups, fluorinated bicyclic fragments, and stereochemically defined bicyclic amine or azabicyclic moieties.

Claims Coverage

The consolidated claim coverage includes one broad independent Formula I compound claim and, in some items, a second independent claim selecting from a specified set of compounds. Across the items, the claims emphasize the Formula I scaffold, the X5/X7 assignments, the R2/R3 ring-forming linkage, and the structured options for R6 and other substituents; several items also include pharmaceutical composition claims.

Formula I compound with defined X5 and X7 positions

A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X5 is N and X7 is CH or CF, with variable substituents R1 through R17 and additional parameters defined by the claim.

R2 and R3 heterocycle formation linkage

R2 and R3 are taken together with the atoms to which they are attached to form an optionally substituted 6 to 8 membered heterocyclyl ring.

R6 linkage architecture defined as -L-R13

R6 is defined by multiple functional-group options including -N(R14)S(O)2R9, -N(R14)C(O)OR9, -OC(O)R9, -OC(O)OR9, -L-R13, and -OR15, with L as C1-8 alkylene, C1-8 haloalkylene, or 5-10 membered heteroarylene, and R13 selected from enumerated functional-group and cycloalkyl options.

Variable substituent constraints for R1, R2, R3, R4, R8, R9, R12, R14, R15, and R17

The claims define extensive substituent options for R1, R2, R3, R4, R8, R9, R12, R14, R15, and R17, including halo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, nitro, azido, cyano, hydroxy, oxo, and other heteroatom-containing groups, with optional substitution limits such as 1 to 5 Z1 or related substitution counts.

Pharmaceutical composition with excipient

A pharmaceutical composition comprising a compound according to Formula I or claim 1, together with at least one pharmaceutically acceptable excipient.

Pharmaceutical composition including a Janus kinase inhibitor

A pharmaceutical composition including the excipient-containing composition and further comprising at least one additional therapeutic agent that is a Janus kinase inhibitor.

Selected compound from a specified set

A compound selected from a specified set of compounds, or a pharmaceutically acceptable salt thereof.

Overall, the claim coverage centers on a broad Formula I compound framework with extensive variable substituent definitions and the R2/R3 heterocycle-forming constraint. The claims are further narrowed by specific substituent selections and extended to pharmaceutical compositions with excipients, compositions including a Janus kinase inhibitor, and in one item a claim to a selected compound from a specified set.

Stated Advantages

Not explicitly described in patent.

Documented Applications

PAD4-mediated diseases (treatment) via administration or use of the Formula I/IB compounds.

Rheumatoid arthritis.

Cancer treatment using Formula I compounds in combination with a JAK-1 inhibitor.

Pharmaceutical compositions containing the claimed compound together with a pharmaceutically acceptable excipient.

Pharmaceutical compositions further comprising at least one additional therapeutic agent that is a Janus kinase inhibitor.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.